{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:01:54Z","timestamp":1784818914617,"version":"3.55.0"},"reference-count":73,"publisher":"BMJ","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and safety of dual sodium glucose cotransporter (SGLT) 1\/2 inhibitor sotagliflozin in type 1 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Meta-analysis of randomised controlled trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>Medline; Cochrane Library; Embase; international meeting abstracts; international and national clinical trial registries; and websites of US, European, and Japanese regulatory authorities, up to 10 January 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Eligibility criteria for selecting studies<\/jats:title><jats:p>Randomised controlled trials evaluating the effect of sotagliflozin versus active comparators or placebo on glycaemic and non-glycaemic outcomes and on adverse events in type 1 diabetes in participants older than 18. Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarised strength of evidence using the grading of recommendations assessment, development, and evaluation approach. Main outcomes were pooled using random effects models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 739 records identified, six randomised placebo controlled trials (n=3238, duration 4-52 weeks) were included. Sotagliflozin reduced levels of glycated haemoglobin (HbA1c; weighted mean difference \u22120.34% (95% confidence interval \u22120.41% to \u22120.27%), P&lt;0.001); fasting plasma glucose (\u221216.98 mg\/dL, \u221222.1 to \u221211.9; 1 mg\/dL=0.0555 mmol\/L) and two hour-postprandial plasma glucose (\u221239.2 mg\/dL, \u221250.4 to \u221228.1); and daily total, basal, and bolus insulin dose (\u22128.99%, \u221210.93% to \u22127.05%; \u22128.03%, \u221210.14% to \u22125.93%; \u22129.14%, \u221212.17% to \u22126.12%; respectively). Sotagliflozin improved time in range (weighted mean difference 9.73%, 6.66% to 12.81%) and other continuous glucose monitoring parameters, and reduced body weight (\u22123.54%, \u22123.98% to \u22123.09%), systolic blood pressure (\u22123.85 mm Hg, \u22124.76 to \u22122.93), and albuminuria (albumin:creatinine ratio \u221214.57 mg\/g, \u221226.87 to \u22122.28). Sotagliflozin reduced hypoglycaemia (weighted mean difference \u22129.09 events per patient year, \u221213.82 to \u22124.36) and severe hypoglycaemia (relative risk 0.69, 0.49 to 0.98). However, the drug increased the risk of ketoacidosis (relative risk 3.93, 1.94 to 7.96), genital tract infections (3.12, 2.14 to 4.54), diarrhoea (1.50, 1.08 to 2.10), and volume depletion events (2.19, 1.10 to 4.36). Initial HbA1c and basal insulin dose adjustment were associated with the risk of diabetic ketoacidosis. A sotagliflozin dose of 400 mg\/day was associated with a greater improvement in most glycaemic and non-glycaemic outcomes than the 200 mg\/day dose, without increasing the risk of adverse events. The quality of evidence was high to moderate for most outcomes, but low for major adverse cardiovascular events and all cause death. The relatively short duration of trials prevented assessment of long term outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmj.l1328","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T17:35:50Z","timestamp":1554831350000},"page":"l1328","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8569-2872","authenticated-orcid":false,"given":"Giovanni","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cassader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"key20190410000251_ref1","unstructured":"US Center for Disease Control and Prevention. 2019. https:\/\/www.cdc.gov\/diabetes\/library\/socialmedia\/infographics.html."},{"key":"key20190410000251_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03062-6"},{"key":"key20190410000251_ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0078"},{"key":"key20190410000251_ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"key20190410000251_ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2112"},{"key":"key20190410000251_ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S008"},{"key":"key20190410000251_ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"key20190410000251_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795"},{"key":"key20190410000251_ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"key20190410000251_ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0615"},{"key":"key20190410000251_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.10.014"},{"key":"key20190410000251_ref12","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0063"},{"key":"key20190410000251_ref13","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0205"},{"key":"key20190410000251_ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03127.x"},{"key":"key20190410000251_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4423-z"},{"key":"key20190410000251_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4422-0"},{"key":"key20190410000251_ref17","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0029"},{"key":"key20190410000251_ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1600"},{"key":"key20190410000251_ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"key20190410000251_ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S006"},{"key":"key20190410000251_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.061"},{"key":"key20190410000251_ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13260"},{"key":"key20190410000251_ref23","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.214304"},{"key":"key20190410000251_ref24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203364"},{"key":"key20190410000251_ref25","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1562"},{"key":"key20190410000251_ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2806"},{"key":"key20190410000251_ref27","first-page":"S87","article-title":"Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study)","volume":"60","author":"Bode","year":"2017","journal-title":"Diabetologia"},{"key":"key20190410000251_ref28","first-page":"S409","article-title":"A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4)","volume":"60","author":"Baker","year":"2017","journal-title":"Diabetologia"},{"key":"key20190410000251_ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"key20190410000251_ref30","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0343"},{"key":"key20190410000251_ref31","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0342"},{"key":"key20190410000251_ref32","unstructured":"US Food and Drug Administration. Search results for sotagliflozin. https:\/\/search.usa.gov\/search?utf8=%E2%9C%93&affiliate=fda&query=sotagliflozin&commit=Search"},{"key":"key20190410000251_ref33","unstructured":"European Medicines Agency. Search results for sotagliflozin. https:\/\/www.ema.europa.eu\/en\/search\/search?search_api_views_fulltext=sotagliflozin"},{"key":"key20190410000251_ref34","unstructured":"Pharmaceutical and Medical Devices Agency. Search results for sotagliflozin. https:\/\/ss.pmda.go.jp\/en_all\/search.x?q=sotagliflozin&ie=UTF-8&page=1&x=30&y=11"},{"key":"key20190410000251_ref35","unstructured":"Lexicon Pharmaceuticals. Homepage. 2019. www.lexpharma.com"},{"key":"key20190410000251_ref36","unstructured":"Sanofi. Homepage. 2019. https:\/\/www.sanofi.com"},{"key":"key20190410000251_ref37","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000134501.57864.66"},{"key":"key20190410000251_ref38","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2375"},{"key":"key20190410000251_ref39","unstructured":"US Food and Drug Administration. FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes. 2018. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm611454.htm"},{"key":"key20190410000251_ref40","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0090"},{"key":"key20190410000251_ref41","unstructured":"Medical dictionary for regulatory activities. Homepage. https:\/\/www.meddra.org\/. Accessed 21 July 2018."},{"key":"key20190410000251_ref42","unstructured":"Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.2.0. Cochrane Collaboration, updated March 2011. 14 July 2017. https:\/\/community.cochrane.org\/editorial-and-publishing-policy-resource\/cochrane-review-development\/cochrane-handbooks\/cochrane-handbook-systematic-reviews-interventions"},{"key":"key20190410000251_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.12.004"},{"key":"key20190410000251_ref44","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602688"},{"key":"key20190410000251_ref45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-2012-0574","article-title":"Sponsorship bias in clinical research","volume":"24","author":"Lexchin","year":"2012","journal-title":"Int J Risk Saf Med"},{"key":"key20190410000251_ref46","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-200209000-00002"},{"key":"key20190410000251_ref47","volume-title":"The prevention and treatment of missing data in clinical trials","author":"National Research Council. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education","year":"2010"},{"key":"key20190410000251_ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.15.1813"},{"key":"key20190410000251_ref49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.5694\/j.1326-5377.2005.tb06813.x","article-title":"Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience","volume":"182","author":"Henry","year":"2005","journal-title":"Med J Aust"},{"key":"key20190410000251_ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1645"},{"key":"key20190410000251_ref51","unstructured":"Manager R. (RevMan). Version 5.3. Copenhagen, Denmark: Nordic Cochrane Center, Cochrane Collaboration; 2012. https:\/\/community.cochrane.org\/help\/tools-and-software\/revman-5"},{"key":"key20190410000251_ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"key20190410000251_ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.03.017"},{"key":"key20190410000251_ref54","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2528"},{"key":"key20190410000251_ref55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j573"},{"key":"key20190410000251_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"key20190410000251_ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"key20190410000251_ref58","unstructured":"European Association for the Study of Diabetes. Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study). EASD virtual meeting, oral presentation 186. 2017. https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/efficacy-and-safety-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-to-insulin-in-young-adults-with-poorly-controlled-type-1-diabetes-jdrf-study-15ae18d4-b8f6-439c-87ea-2f19dcad388e"},{"key":"key20190410000251_ref59","unstructured":"European Association for the Study of Diabetes. A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4). EASD virtual meeting, ePoster 186. 2017. https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/a-12-week-dose-ranging-study-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-therapy-to-insulin-in-type-1-diabetes-intandem4-eac92dc0-58bd-48ae-9cba-aa1675a947cf"},{"key":"key20190410000251_ref60","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1669"},{"key":"key20190410000251_ref61","unstructured":"NovoNordisk. Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211). Company announcement 51\/2015. https:\/\/www.novonordisk.com\/bin\/getPDF.1947182.pdf. Accessed 24 October 2018."},{"key":"key20190410000251_ref62","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"key20190410000251_ref63","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1769"},{"key":"key20190410000251_ref64","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.11.1683"},{"key":"key20190410000251_ref65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035901"},{"key":"key20190410000251_ref66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"key20190410000251_ref67","unstructured":"Janssen Research & Development. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. 11 December 2012. www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVOKANA-pi.pdf (accessed 13 September 2014)."},{"key":"key20190410000251_ref68","first-page":"212262","article-title":"Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"3","author":"Neumiller","year":"2014","journal-title":"Drugs Context"},{"key":"key20190410000251_ref69","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"key20190410000251_ref70","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12882"},{"key":"key20190410000251_ref71","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12496"},{"key":"key20190410000251_ref72","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"key20190410000251_ref73","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [correction: Lancet Diabetes Endocrinol 2017;5:864-76]","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.l1328","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.l1328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T21:55:29Z","timestamp":1607205329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.l1328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":73,"alternative-id":["10.1136\/bmj.l1328"],"URL":"https:\/\/doi.org\/10.1136\/bmj.l1328","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]}}}